HomeCompareSELB vs CL

SELB vs CL: Dividend Comparison 2026

SELB yields 226.96% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SELB wins by $252.97M in total portfolio value
10 years
SELB
SELB
● Live price
226.96%
Share price
$0.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$253.01M
Annual income
$135,537,151.87
Full SELB calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — SELB vs CL

📍 SELB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSELBCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SELB + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SELB pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SELB
Annual income on $10K today (after 15% tax)
$19,291.87/yr
After 10yr DRIP, annual income (after tax)
$115,206,579.09/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, SELB beats the other by $115,201,987.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SELB + CL for your $10,000?

SELB: 50%CL: 50%
100% CL50/50100% SELB
Portfolio after 10yr
$126.53M
Annual income
$67,771,276.91/yr
Blended yield
53.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

SELB
Analyst Ratings
10
Buy
1
Hold
Consensus: Buy
Altman Z
-3.6
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SELB buys
0
CL buys
0
No recent congressional trades found for SELB or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSELBCL
Forward yield226.96%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$253.01M$40.8K
Annual income after 10y$135,537,151.87$5,401.96
Total dividends collected$240.02M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: SELB vs CL ($10,000, DRIP)

YearSELB PortfolioSELB Income/yrCL PortfolioCL Income/yrGap
1← crossover$33,396$22,696.32$11,012$312.01+$22.4KSELB
2$106,573$70,838.67$12,196$412.95+$94.4KSELB
3$325,301$211,268.16$13,599$549.66+$311.7KSELB
4$950,756$602,683.85$15,288$736.64+$935.5KSELB
5$2,663,535$1,646,225.90$17,353$995.28+$2.65MSELB
6$7,160,158$4,310,175.78$19,926$1,357.80+$7.14MSELB
7$18,490,047$10,828,678.09$23,194$1,873.82+$18.47MSELB
8$45,918,422$26,134,071.85$27,439$2,621.52+$45.89MSELB
9$109,788,499$60,655,787.13$33,088$3,727.38+$109.76MSELB
10$253,010,846$135,537,151.87$40,806$5,401.96+$252.97MSELB

SELB vs CL: Complete Analysis 2026

SELBStock

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Full SELB Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this SELB vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SELB vs SCHDSELB vs JEPISELB vs OSELB vs KOSELB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.